Valuation
- Market cap
- 1,000
- Revenue TTM
- $1,490,000
- Net income TTM
- $-101,850,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -6,835.57%
- Debt to equity
- 0.00
Trading
- Volume
- 400
- Avg volume
- 16,684
- Day's range
- $0.00 – $0.00
- Shares out
- 13,340,000
- Stochastic %K
- 0%
- Beta
- 0.10
- Analysts
- Strong Buy
- Price target
- —
Company profile
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby...
Show more
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 888 613 8802
- Website
- https://www.staterabiopharma.com
- Address
- 4333 Corbett Drive,, Suite 1082, Fort Collins, United States
Latest news
No headlines yet.
